Award
National Institute of Allergy and Infectious Diseases 5R44AI170392-04
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites
Recipient
EMMUNE, INC
Award Amount
$1,000,000.00
Ceiling
$1,000,000.00
Awarded
August 05, 2025
Identifier
5R44AI170392-04
This award funds the development of improved SARS-CoV-2 vaccine antigens that target conserved neutralizing epitopes in the receptor binding domain of the virus, using engineered glycosylation sites and lipid nanoparticle mRNA vaccine technology to enhance immune response and address variant challenges.
Description
Development of vaccine antigens for SARS-CoV-2 focusing the antibody response onto neutralizing epitopes in the receptor binding domain (RBD) of the viral Spike (S) protein. The project aims to enhance immunogenicity of RBD antigens delivered as lipid nanoparticle (LNP)-mRNA vaccines and optimize boosters based on variant-derived RBD versus full-length S protein to focus antibody responses onto conserved neutralizing epitopes among SARS-CoV-2 variants.